Accessories to the crime: Recent advances in HIV accessory protein biology

Current HIV/AIDS Reports

Volumn 6, Issue 1, 2009, Pages 36-42

  Gramberg, Thomas ^b   Sunseri, Nicole ^b   Landau, Nathaniel R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; CD4 ANTIGEN; CELL SURFACE PROTEIN; CYTIDINE DEAMINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN DERIVATIVE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIRION INFECTIVITY FACTOR; VIRUS RNA; VPR PROTEIN; VPU PROTEIN; VPX PROTEIN; PROTEIN; VIF PROTEIN;

COMPREHENSION; DEGRADATION; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MODULATION; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; NONHUMAN; REVIEW; RNA BINDING; VIRION; VIRUS GENE; VIRUS REPLICATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOGENICITY; PHYSIOLOGY;

ANIMALS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, VPR; HIV-1; HUMANS; PROTEINS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 61449214207     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0006-z     Document Type: Review

References (50)

1. Goila-Gaur R, Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51.
2. Chiu YL, Greene WC: APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J Biol Chem 2006, 281:8309-8312.
3. Sheehy AM, Gaddis NC, Choi JD, et al.: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
4. Jarmuz A, Chester A, Bayliss J, et al.: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
5. Teng B, Burant CF, Davidson NO: Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993, 260:1816-1819.
6. Yu Q, Konig R, Pillai S, et al.: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004, 11:435-442.
7. • Chelico L, Pham P, Calabrese P, et al.: APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat Struct Mol Biol 2006, 13:392-399. The study used oligonucleotide substrates to show how APOBEC3G slides and jumps on single-stranded DNA.
8. Xu H, Chertova E, Chen J, et al.: Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007, 360:247-256.
9. Yu X, Yu Y, Liu B, et al.: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
10. Mehle A, Strack B, Ancuta P, et al.: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004, 279:7792-7798.
11. Yu Y, Xiao Z, Ehrlich ES, et al.: Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004, 18:2867-2872.
12. Hache G, Liddament MT, Harris RS: The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem 2005, 280:10920-10924.
13. Navarro F, Bollman B, Chen H, et al.: Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333:374-386.
14. Schafer A, Bogerd HP, Cullen BR: Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004, 328:163-168.
15. Santiago ML, Montano M, Benitez R, et al.: APOBEC3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008, 321:1343-1346.
16. Okeoma CM, Lovsin N, Peterlin BM, et al.: APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 2007, 445:927-930.
17. Kazazian HH Jr: Mobile elements: drivers of genome evolution. Science 2004, 303:1626-1632.
18. Bogerd HP, Wiegand HL, Doehle BP, et al.: APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006, 34:89-95.
19. • Chen H, Lilley CE, Yu Q, et al.: APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006, 16:480-485. The study shows that APOBEC3A does not restrict retroviruses but is a potent inhibitor of adeno-associated virus and murine retrotransposons.
20. Esnault C, Heidmann O, Delebecque F, et al.: APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433:430-433.
21. Sawyer SL, Emerman M, Malik HS: Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004, 2:E275.
22. Tristem M, Marshall C, Karpas A, et al.: Evolution of the primate lentiviruses: evidence from Vpx and Vpr. Embo J 1992, 11:3405-3412.
23. Gibbs JS, Lackner AA, Lang SM, et al.: Progression to AIDS in the absence of a gene for Vpr or Vpx. J Virol 1995, 69:2378-2383.
24. Paxton W, Connor RI, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. J Virol 1993, 67:7229-7237.
25. Yamashita M, Emerman M: The cell cycle independence of HIV infections is not determined by known karyophilic viral elements. PLoS Pathog 2005, 1:e18.
26. Goh WC, Rogel ME, Kinsey CM, et al.: HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med 1998, 4:65-71.
27. Andersen JL, Le Rouzic E, Planelles V: HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 2008, 85:2-10.
28. Zhang S, Feng Y, Narayan O, et al.: Cytoplasmic retention of HIV-1 regulatory protein Vpr by protein-protein interaction with a novel human cytoplasmic protein VprBP. Gene 2001, 263:131-140.
29. Hrecka K, Gierszewska M, Srivastava S, et al.: Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 2007, 104:11778-11783.
30. Schrofelbauer B, Hakata Y, Landau NR: HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci U S A 2007, 104:4130-4135.
31. Belzile JP, Duisit G, Rougeau N, et al.: HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog 2007, 3:e85.
32. Le Rouzic E, Belaidouni N, Estrabaud E, et al.: HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 2007, 6:182-188.
33. Lee J, Zhou P: DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 2007, 26:775-780.
34. Goujon C, Jarrosson-Wuilleme L, Bernaud J, et al.: With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther 2006, 13:991-994.
35. • Goujon C, Riviere L, Jarrosson-Wuilleme L, et al.: SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology 2007, 4:2. The study used VLPs to show that Vpx appears to counteract an antiviral mechanism that involves the proteasome system in DCs.
36. Srivastava S, Swanson SK, Manel N, et al.: Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 2008, 4:e1000059.
37. • Sharova N, Wu Y, Zhu X, et al.: Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog 2008, 4:e1000057. Permissive and nonpermissive cells were fused to show that DCs contain a dominant inhibitor that is counteracted by Vpx.
38. Nomaguchi M, Fujita M, Adachi A: Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes Infect 2008, 10:960-967.
39. Malim MH, Emerman M: HIV-1 accessory proteins - ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398.
40. Hill MS, Ruiz A, Pacyniak E, et al.: Modulation of the severe CD4+ T-cell loss caused by a pathogenic simianhuman immunodeficiency virus by replacement of the subtype B Vpu with the Vpu from a subtype C HIV-1 clinical isolate. Virology 2008, 371:86-97.
41. Kerkau T, Bacik I, Bennink JR, et al.: The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997, 185:1295-1305.
42. Hussain A, Wesley C, Khalid M, et al.: Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol 2008, 82:893-902.
43. Klimkait T, Strebel K, Hoggan MD, et al.: The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. J Virol 1990, 64:621-629.
44. Neil SJ, Eastman SW, Jouvenet N, et al.: HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2006, 2:e39.
45. Neil SJ, Sandrin V, Sundquist WI, et al.: An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2:193-203.
46. Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
47. Bartee E, McCormack A, Fruh K: Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2006, 2:e107.
48. •• Van Damme N, Goff D, Katsura C, et al.: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252. This study independently identified BST2/tetherin as the target of Vpu.
49. Gottlinger HG: HIV/AIDS: virus kept on a leash. Nature 2008, 451:406-408.
50. • Varthakavi V, Heimann-Nichols E, Smith RM, et al.: Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nat Med 2008, 14:641-647. This study identified CAML as a second potential target of Vpu using a yeast-two hybrid approach. Whether CAML regulates or otherwise interacts with tetherin/BST2 is not yet known.